Last reviewed · How we verify
rhPro-UK simulation agent
rhPro-UK is a recombinant human prourokinase that converts plasminogen to plasmin to dissolve blood clots.
rhPro-UK is a recombinant human prourokinase that converts plasminogen to plasmin to dissolve blood clots. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.
At a glance
| Generic name | rhPro-UK simulation agent |
|---|---|
| Sponsor | Tasly Biopharmaceuticals Co., Ltd. |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Thrombosis |
| Phase | Phase 3 |
Mechanism of action
Prourokinase (pro-UK) is a serine protease precursor that acts as a fibrinolytic agent. When administered, it is converted to its active form (urokinase) which then activates plasminogen to plasmin, leading to degradation of fibrin in thrombi. This mechanism makes it useful for thrombolytic therapy in acute thrombotic conditions.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary embolism
Common side effects
- Bleeding / hemorrhage
- Intracranial hemorrhage
- Allergic reactions
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhPro-UK simulation agent CI brief — competitive landscape report
- rhPro-UK simulation agent updates RSS · CI watch RSS
- Tasly Biopharmaceuticals Co., Ltd. portfolio CI